HC Wainwright Reaffirms “Buy” Rating for Jade Biosciences (NASDAQ:JBIO)

Jade Biosciences (NASDAQ:JBIO)‘s stock had its “buy” rating reiterated by analysts at HC Wainwright in a research report issued on Thursday, Marketbeat Ratings reports. They presently have a $55.00 price target on the stock. HC Wainwright’s target price points to a potential upside of 289.44% from the company’s previous close.

JBIO has been the subject of several other research reports. Jefferies Financial Group restated a “buy” rating and issued a $48.00 target price on shares of Jade Biosciences in a report on Tuesday, August 11th. Wedbush restated an “outperform” rating and issued a $47.00 target price on shares of Jade Biosciences in a report on Thursday. BTIG Research raised their target price on shares of Jade Biosciences from $74.00 to $77.00 and gave the stock a “buy” rating in a report on Monday, August 10th. UBS Group began coverage on shares of Jade Biosciences in a report on Monday, June 15th. They issued a “buy” rating and a $45.00 target price for the company. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Jade Biosciences in a report on Friday, September 11th. Two research analysts have rated the stock with a Strong Buy rating, six have issued a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $51.75.

Jade Biosciences Trading Up 0.5%

Shares of NASDAQ:JBIO traded up $0.07 during midday trading on Thursday, reaching $14.12. 420,397 shares of the company were exchanged, compared to its average volume of 748,490. The business’s fifty day moving average is $19.69 and its two-hundred day moving average is $19.74. Jade Biosciences has a one year low of $8.16 and a one year high of $28.00. The stock has a market cap of $898.22 million, a PE ratio of -7.36 and a beta of 1.45.

Jade Biosciences (NASDAQ:JBIO) last released its quarterly earnings data on Monday, August 10th. The company reported ($0.76) EPS for the quarter, missing the consensus estimate of ($0.66) by ($0.10). As a group, sell-side analysts expect that Jade Biosciences will post -2.89 EPS for the current year.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in the business. Engineers Gate Manager LP purchased a new position in Jade Biosciences during the 2nd quarter valued at about $503,000. Maven Securities LTD purchased a new position in Jade Biosciences during the 2nd quarter valued at about $1,111,000. Squarepoint Ops LLC increased its position in Jade Biosciences by 22.0% during the 2nd quarter. Squarepoint Ops LLC now owns 54,456 shares of the company’s stock valued at $1,210,000 after purchasing an additional 9,806 shares during the period. Corient Private Wealth LP purchased a new position in Jade Biosciences during the 2nd quarter valued at about $1,367,000. Finally, Bank of New York Mellon Corp purchased a new position in Jade Biosciences during the 2nd quarter valued at about $1,896,000.

Key Headlines Impacting Jade Biosciences

Here are the key news stories impacting Jade Biosciences this week:

• Positive Sentiment: HC Wainwright reaffirmed its “buy” rating and set a $55 price target, implying substantial potential upside from recent trading levels. The bullish view provides a positive analyst catalyst, although price targets are not guarantees. Benzinga coverage
• Positive Sentiment: JADE301 produced encouraging preclinical results in development for dermatomyositis. Jade said the half-life-extended anti-IFN-β antibody demonstrated selective, high-affinity binding and greater functional potency than a dazukibart comparator in disease-relevant human cells. Jade Biosciences JADE301 preclinical data
• Positive Sentiment: In non-human primates, JADE301 had an approximately 25-day half-life, predictable distribution into muscle and favorable tolerability across tested subcutaneous doses. These findings support Jade’s goal of developing an infrequently dosed treatment. Yahoo Finance report
• Positive Sentiment: Jade expects to begin a Phase 1 healthy-volunteer trial in the fourth quarter of 2026, with interim data anticipated in the second half of 2027. Advancing toward clinical testing represents an important milestone for the biotechnology company. RTTNews Phase 1 update
• Neutral Sentiment: Jade presented the JADE301 program profile and preclinical findings at EADV 2026 through a conference call, transcript and slideshow. The materials add visibility but do not yet provide clinical efficacy or safety results in patients. Seeking Alpha presentation
• Negative Sentiment: JADE301 remains an early-stage, preclinical asset. The program still faces clinical, regulatory and financing risks, and the anticipated interim data are not expected until 2027. Consequently, investors may be discounting the positive laboratory results until human trial data become available.

About Jade Biosciences

Jade Biosciences, Inc (NASDAQ: JBIO) is a clinical-stage biotechnology company focused on developing medicines for autoimmune and inflammatory diseases. The company uses antibody-based drug discovery and development approaches to pursue therapies intended to address significant unmet medical needs.

Jade Biosciences is advancing a pipeline of investigational programs and does not currently have commercially marketed products. Its work is centered on identifying and developing targeted therapies that may modulate biological pathways involved in autoimmune disease.

The company’s activities primarily consist of research, preclinical development and clinical evaluation of its drug candidates.